Table 3.

Clinical and Mycologic Outcomes at Days 42 and 180 in 88 Patients With Endemic Mycoses Enrolled in Study Comparing Conventional and Super-Bioavailability Itraconazole, 2018–2021

Outcome	Patients, No. (%)
	Day 42		Day 180
	Clinical	Mycologic	Clinical	Mycologic
SUBA-itra group (n = 42)
Success	29 (69)	19 (45)	25 (60)	17 (40)
Failure	8 (19)	9 (21)	6 (14)	7 (17)
Unevaluable	5 (12)	14 (33)	11 (26)	18 (43)
c-itra group (n = 46)
Success	31 (67)	22 (48)	30 (65)	22 (48)
Failure	7 (15)	14 (30)	5 (11)	9 (20)
Unevaluable	8 (17)	10 (22)	11 (24)	15 (33)

Abbreviations: c-itra, conventional itraconazole; SUBA-itra, SUBA itraconazole.